Proceedings of the International Cancer Imaging Society (ICIS) 18th Annual Teaching Course

  title={Proceedings of the International Cancer Imaging Society (ICIS) 18th Annual Teaching Course},
  author={G P Der Balian and Jason Kempton Slack and Brian Clevinger and Herv{\'e} Bazin and Joseph M. Davie},
  journal={Cancer Imaging},
Whole body MRI is recognized as the most sensitive imaging test for the diagnosis of myeloma bone involvement and is recommended by the International Myeloma Working Group for work up of patients with asymptomatic myeloma or solitary plasmacytoma [1]. In some countries such as the United Kingdom, whole body MRI is now recommended as first line imaging in all patients with a suspected diagnosis of myeloma [2]. This is because abnormal signal on MRI has been shown to be associated with very high… 


Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response
It is concluded that early lesional sFF changes may provide important information on depth of response, and are worthy of further prospective study.
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
There is a subgroup of patients who have a substantial risk of progression to symptomatic disease that can be detected at diagnosis (either by extensive BM infiltration⩽60% or FLC ratio⩾100) and may be considered for immediate treatment.
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO) incidence and epidemiology Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
  • A. Younes, P. Hilden, V. Seshan
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
It is demonstrated that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions, and a new lymphoma response criteria (RECIL 2017) was developed.
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
Investigating the prognostic value of metabolic heterogeneity in 103 patients with PMBCL prospectively enrolled in the IELSG 26 study aimed at clarifying the role of PET in this lymphoma subtype resulted in early and accurate identification of patients at high risk for progression at a point that would allow the use of risk-adapted treatments.
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
The integration of FDG-PET and CT, as in the combined hybrid PET/CT scanners now available, will not only optimize the evaluation of patients with GIST treated with molecularly targeted drugs, but may ultimately help shorten clinical trials, and accelerate drug development in this disease and other cancers as well.
Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
In patients with FDG-avid lymphoma, DWI-MRI seems to be only slightly inferior to 18F-FDG-PET/CT with regard to pretherapeutic regional assessment and staging.
Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study
It is confirmed that 18F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging, and the interobserver agreement for BMI in this study proved excellent and only focal 18F -FDG BM uptake should be considered as a harbinger of HL.